Navigating Prostate Cancer Progression: Risk Assessment and Management

A brief review of the evolving realm of prostate cancer care centered on the significance of identifying high-risk cases and addressing the complexities of risk stratification and prognosis.

EP: 1.Optimizing Prostate Cancer Care: A Collaborative Approach

EP: 2.Choosing Partners in Cancer Care: A Strategic Approach

EP: 3.Early-Stage Prostate Cancer Screening and Management Trends

Now Viewing

EP: 4.Navigating Prostate Cancer Progression: Risk Assessment and Management

EP: 5.Prostate Cancer Hormone Therapies: A Comprehensive Overview

EP: 6.Enhancing Efficacy in Advanced Hormone-Sensitive Prostate Cancer Treatment

EP: 7.Advanced Prostate Cancer: Enhancing Combination Therapy

EP: 8.Overcoming Barriers to Triplet Therapy in Prostate Cancer

EP: 9.Advanced Prostate Cancer: Patient Care Continuity

EP: 10.Optimizing Care Collaboration in Advanced Prostate Cancer

Related Videos

Related Content

Advertisement

December 12th 2024

Published data show noninferior treatment-free survival with HIFU vs RP

Hannah Clarke

Specifically, 90% of patients in the HIFU arm vs 86% of patients in the radical prostatectomy arm were free from subsequent definitive treatment at 30 months.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

December 5th 2024

FDA fast tracks PT217 for neuroendocrine prostate cancer

Hannah Clarke

PT217 is currently under investigation in the phase 1/2 SKYBRIDGE trial in patients with neuroendocrine cancers.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

December 3rd 2024

JANX007 demonstrates encouraging clinical activity in mCRPC

Hannah Clarke

Data showed that all patients achieved a PSA decline of at least 50%.

December 2nd 2024

Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer

Hannah Clarke

“The combination of pembrolizumab and chemotherapy presents a promising new treatment approach for these challenging-to-treat, rare cancers and could be a major breakthrough for patient care,” says Arnold I. Chin, MD, PhD.

Related Content

Advertisement

December 12th 2024

Published data show noninferior treatment-free survival with HIFU vs RP

Hannah Clarke

Specifically, 90% of patients in the HIFU arm vs 86% of patients in the radical prostatectomy arm were free from subsequent definitive treatment at 30 months.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

December 5th 2024

FDA fast tracks PT217 for neuroendocrine prostate cancer

Hannah Clarke

PT217 is currently under investigation in the phase 1/2 SKYBRIDGE trial in patients with neuroendocrine cancers.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

December 3rd 2024

JANX007 demonstrates encouraging clinical activity in mCRPC

Hannah Clarke

Data showed that all patients achieved a PSA decline of at least 50%.

December 2nd 2024

Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer

Hannah Clarke

“The combination of pembrolizumab and chemotherapy presents a promising new treatment approach for these challenging-to-treat, rare cancers and could be a major breakthrough for patient care,” says Arnold I. Chin, MD, PhD.